MATRIX METALLOPROTEINASE 9 DRIVES THE SHEDDING OF CD31 IN ACUTE CORONARY SYNDROMES
Giovanna Liuzzo(Agostino Gemelli University Polyclinic), Filippo Crea(Università Cattolica del Sacro Cuore), Anna Severino(Università Cattolica del Sacro Cuore), Ramona Vinci(Unknown), Daniela Pedicino(Agostino Gemelli University Polyclinic), Francesco Trotta(Italian Medicines Agency), Giulia Angelini(Università Cattolica del Sacro Cuore), Giuseppe Pio Piemontese(Università Cattolica del Sacro Cuore), Ada Francesca Giglio(Università Cattolica del Sacro Cuore), Davide Flego(Università Cattolica del Sacro Cuore), Luigi M. Biasucci(Agostino Gemelli University Polyclinic)
Cited by 0
Related Papers
Ischemia and No Obstructive Coronary Artery Disease (INOCA)
|Circulation|2017|745
Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial
|The Lancet|2023|338
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials
|European Heart Journal|2021|150
Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
|Frontiers in Physiology|2019|130